Kriya, a Redwood City CA, and Research Triangle Park, NC-based gene therapy company, acquired Redpin Therapeutics, a New York-based biotechnology company.
The amount of the deal was not disclosed.
The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).
Led by CEO Dr. Elma Hawkins, Redpin Therapeutics is a preclinical stage gene therapy company developing a proprietary chemogenetics platform for targeted cell therapies to address currently intractable diseases of the central nervous system. Its technology utilizes gene therapy to express engineered ion channels that are responsive to modulation by the FDA-approved anti-smoking drug varenicline to either inhibit specific overactive neurons or stimulate underactive ones. Redpin has a worldwide exclusive license from the Howard Hughes Medical Institute for the therapeutic use of this technology, Investors included 4BIO Capital, Arkin Bio Ventures, Takeda Ventures Inc, New York Ventures and Alexandria Venture Investments.
Led by Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer, Kriya is an integrated company providing technologies and therapeutics in gene therapy. It is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in metabolic disorders, neurology and ophthalmology. Kriya is backed by life sciences and technology investors, and has core operations in Silicon Valley, California and Research Triangle Park, North Carolina.